DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02507128

UnknownPhase NA

Effects of Glucagon Like Peptide-1 on No-reflow

Effects of Glucagon Like Peptide-1 on No-reflow in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Lead sponsor

Chen Wei Ren, MD

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

190

estimated

Study population

Cardiovascular disease

Key I/E criterion

—

Primary endpoint

•A change in the prevalence of no-reflow

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02507128
Org study ID301xnk

Timeline

Milestones

Study first posted2015-07-23estimated
Last update posted2015-07-23estimated
Study start2015-07 (month precision)
Primary completion2016-07estimated (month precision)
Study completion2016-07estimated (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Cardiovascular disease

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

Patients with ST-segment elevation myocardial infarction were eligible for the study.

Exclusion criteria

Patients were excluded for the following reasons: unconscious at presentation; had cardiogenic shock, hypoglycaemia, or diabetic ketoacidosis; had a history of myocardial infarction, stent thrombosis, or renal insufficiency; or had previously undergone coronary artery bypass surgery.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Cardiovascular outcomes
1
Cardiometabolic biomarkers
1
Safety / tolerability / PK
1

Cardiovascular outcomes

1 endpoint
Primary/protocol endpoint/low confidence

a change in the prevalence of no-reflow

Time frame:immediately after PCI

categorical status, improvement

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

a change in high-sensitivity C-reactive protein (hsCRP)

Time frame:immediately after PCI, at 1,3,5 days after PCI

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Safety / tolerability / PK

1 endpoint
Other/protocol endpoint

differences in the incidences of treatment-emergent adverse events

Time frame:immediately after PCI, at 1,3,5 days after PCI

Treatment-emergent AEs (any)

event count, event

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

a change in troponin T

Time frame:immediately after PCI, at 1,3,5 days after PCI

change from baseline, improvement

Secondary/protocol endpoint/low confidence

a change in superoxide dismutase (SOD)

Time frame:immediately after PCI, at 1,3,5 days after PCI

change from baseline, improvement

Publications (5)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.